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Abstract
Objective: Phaeochromocytomas (PCCs) are widely known for their clinical unpredictability. This study
intends to define predictive plasma markers for their variable postoperative behaviour. Furthermore,
the diagnostic accuracy of these plasma tests was determined.
Design and Methods: A retrospective correlative study was performed in a series of 83 operated and
four autopsied patients in order to correlate preoperative catecholamine (CAT) levels of 103 PCCs
with their clinical behaviour. In a subset of cases, chromogranin-A (Chr-A) and enzymes/precursors
of the CAT biosynthesis were studied for their predictive value.
Results: Basal CAT levels were elevated in 81/87 instances (sensitivity: 93%). Four of six cases with
normal measurements showed only medullary hyperplasia. Larger PCCs, particularly those showing
necrosis, capsular and vascular invasion, secreted higher CAT levels. Bilateral, hereditary tumours
were less productive than their unilateral counterparts. Extra-adrenal PCCs secreted significantly
lower levels of epinephrine (EPI) than intra-adrenal tumours. Fourteen patients developed metastases.
According to Kaplan –Meier estimations, patients with higher levels of dopamine, norepinephrine
(NE) and aromatic L-amino acid decarboxylase as well as lower ratios of EPI/EPI  NE, had signifi-
cantly shorter metastases-free intervals. Existence of preoperative hypertension, left ventricular hyper-
trophy and measured blood pressures showed significant positive relationships with CAT levels, but
not with Chr-A.
Conclusions: These data showed that plasma CAT measurement is a sensitive method in the diagnostic
work-up of PCCs. Those tumours producing normal levels are commonly small and asymptomatic.
Furthermore, certain secretion patterns are indicative of the presence of metastases as well as the
size and site of sporadic and syndrome-related PCCs.
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Introduction
Phaeochromocytomas (PCCs), catecholamine (CAT)-
secreting tumours of the sympathoadrenal system,
have fascinated clinicians for decades. Symptoms due
to variable hypersecretion of CATs range from almost
absent in incidentally discovered PCCs to life-threaten-
ing conditions in large degenerating masses. In the
absence of metastases, which occur in 10–25% of
PCCs, no distinction can be made between benign
and malignant tumours (1 –5). Hereditary PCCs are
usually intra-adrenal and commonly bilateral. Extra-
adrenal PCCs (paragangliomas) are frequently multi-
focal (6). The cornerstone of diagnosis is biochemical
evidence of excessive CAT production. For screening
purposes, determination of urinary metanephrine
excretion appears to be the most sensitive test (7).
Recently, measurement of plasma metanephrines has
been reported to be highly sensitive (8, 9) in screening
patients with Von Hippel –Lindau disease (VHL) or mul-
tiple endocrine neoplasia type 2 (MEN2) (10). Never-
theless, the separate measurements of norepinephrine
(NE), epinephrine (EPI) and dopamine (DA) remain of
importance, since specific secretion patterns appear to
be indicative of different clinical entities. Predominantly
EPI-secreting PCCs, which do not lead to elevation of
vanillylmandelic acid (VMA) (11), are relatively small
and more common in cases of MEN2 (12, 13). They
are rarely extra-adrenal in localisation (14) and tend
to degenerate (15). Furthermore, separate measure-
ment of CATs is useful for planning perioperative
pharmacological management. High plasma NE levels
have been associated with the highest degree of intra-
operative haemodynamic instability, whereas absence
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of hypertension has been reported for tumours that
secrete exclusively DA (16) or EPI (11, 17).
It is not clear whether specific secretion patterns are
predictive for a more aggressive behaviour of PCCs. DA
secretion has been reported to be indicative of malig-
nancy (2, 18, 19). Furthermore, a reduced ratio of
EPI and the sum of EPI plus NE was found to be predic-
tive for ectopic localisation, recurrence and metastases
(20). A high level of DA represents a more immature
secretion pattern. Therefore, the study of enzymes
and CAT precursors in the biosynthesis cascade is of
interest. DA-b-hydroxylase (DBH), the enzyme that
converts DA to NE, has been reported to be elevated
in benign PCCs, but has not been studied in malignant
tumours (21 –24). 3,4-Dihydroxyphenylalanine (DOPA)
and aromatic L-amino acid decarboxylase (ALAAD)
appear to be useful prognostic markers for the recur-
rence in neuroblastomas (25), but have not been inves-
tigated in PCCs. Usefulness of chromogranin-A (Chr-A)
determination in PCCs is a matter of controversy, since
high rates of false-negative and false-positive results
have been reported (26). As yet, the usefulness of
Chr-A measurements in the diagnosis of malignant
PCCs has not been established.
In this study, we report our experience with the
determination of basal plasma CAT, DOPA, ALAAD,
DBH and Chr-A concentrations in 87 patients with
PCC diagnosed between 1983 and 1999. This study
intends to define predictive plasma markers for the vari-
able postoperative behaviour of PCCs. Furthermore, the
diagnostic accuracy of these plasma tests was deter-
mined. Plasma levels were therefore correlated with
malignancy, site and size of the tumour, tumour syn-
dromes, and several macroscopic and microscopic
features, which have been claimed to be associated
with specific tumour behaviour. In addition, demo-
graphics, symptoms at presentation, and pre- and peri-
operative features in relation to CAT production were
evaluated in order to define PCC subgroups with
specific patterns of secretion.
Materials and methods
Basal plasma CAT assay
For adequate sampling, an intravenous cannula was
inserted in a forearm vein. Subsequently, patients
rested for 30 min in the supine position. Blood (20 ml)
was collected into two chilled 10 ml heparinised poly-
styrene tubes containing 12 mg glutathione and
plasma was stored at 270 8C. Plasma NE (normal:
,600 pg/ml), EPI (normal: ,100 pg/ml) and DA
(normal: ,100 pg/ml) were measured by high-per-
formance liquid chromatography with fluorimetric or
electrochemical detection (27). For the determination
of plasma Chr-A (normal: ,30 U/l) a commercially
available ELISA kit was used as described previously
(26). ALAAD (normal: ,59 mU/l) was determined by
its ability to form DA from the substrate 3,4-DOPA in
the presence of pyridoxal-5-phosphate as cofactor
(28). DOPA (normal: 3250 pg/ml) was determined
after conversion to DA (29). DBH (normal: ,67 U/l)
was measured using a functional assay as described
previously (30).
Patients and definitions
Basal plasma CAT levels were measured routinely in 87
patients treated for PCCs in our hospital between 1983
and 2001. Only cases with histologically proven intra-
abdominal PCCs were included in this report. Solely
extra-abdominal PCCs were excluded. Malignant PCCs
were defined as metastasised tumours. Metastases
were defined as the presence of PCC tissue at sites
normally devoid of chromaffin tissue, either proven
histologically or identified by 123I-meta-iodobenzyl-
guanidine (MIBG) scintigraphy and/or computed
tomographic (CT) scans in conjunction with raised
serum or urine levels of CAT levels or their metabolites.
Extra-adrenal site was defined as the presence of a CAT-
producing tumour below the diaphragm of the para-
ganglion system, the so-called visceral-autonomic and
aortico-sympathetic phaeochromocytomas, including
tumours of the organ of Zuckerkandl and the sympa-
thetic chain. Follow-up consisted of regular history
taking, physical examination and determination of
urine or serum levels of CATs and/or their urinary
metabolites. We investigated the possible correlation
of preoperative basal plasma CAT levels with the follow-
ing clinical and histopathological features.
Mode of presentation Patients presented with either
typical paroxysms, sustained hypertension (taking anti-
hypertensive drugs and/or blood pressure
$180/95 mmHg in the absence of typical paroxysms),
malignant hypertension (hypertensive emergency with
hypertensive fundus grade III or IV) (31), or were
asymptomatic as in incidentalomas or familial cases
during screening. The duration of the symptoms was
registered. Symptoms that were recorded included
headache, palpitations, spells of perspiration, nausea,
blanching, tremor, vertigo and miscellaneous symp-
toms. Preoperative electrocardiograms were reviewed
and the presence of left ventricular hypertrophy
recorded, according to the voltage criteria of Sokolow
& Lyon (32). Furthermore, it was noted whether
patients presented with a cardiovascular emergency,
necessitating acute intensive care treatment.
Syndromes/neurofibromatosis/sporadic PCCs
Based on family history and, since 1994, on germline
DNA analysis, tumour syndromes were classified as
MEN2A (PCCs, medullary thyroid carcinoma and
hyperparathyroidism), MEN2B (identical but more
aggressive tumours of type 2A, Marphanoid habitus
and mucosal ganglioneuromatosis), VHL (PCCs,
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cerebellar haemangioblastomas, retinal angiomas and
renal, pancreatic and epididymal tumours) or neuro-
fibromatosis type 1 (NF).
Tumour characteristics Tumour site (intra-adrenal or
extra-adrenal), the largest axis, volume and tumour
weight were taken from the pathology reports.
Tumours smaller than 2 cm were as a rule included
in toto. Of larger tumours, two sections were taken
per cm diameter. Histopathology of all primary tumours
and metastases was reviewed by a neutral pathologist
with substantial expertise in endocrine pathology (see
Acknowledgements). Capsular invasion was scored
negative if the capsule was intact or positive when
tumour cells, mostly wedge shaped, invaded into or
through the capsule. Vasoinvasion was scored either
negative if absent or positive if invasion into intra-
tumoural, capsular or surrounding vessels was present.
In addition, existence of tumour degeneration was
recorded as presented by intratumoural necrosis,
haemorrhage or cysts.
Blood pressure measurements Preoperative measure-
ments were performed non-invasively and highest
blood pressure peaks recorded. During surgery, invasive
systolic and diastolic measurements were recorded
before induction and during tumour manipulation.
Blood pressure peak levels and elevation from post-
induction baseline values were recorded.
Statistical analysis
For comparing nominal variables between groups, the
Chi-square test was used. The Mann –Whitney U test
(for two groups) or the Kruskal –Wallis H test (for
three or more groups) were performed to compare
ordinal variables or continuous variables that were
not approximately normally distributed. For quantify-
ing associations between variables, Spearman’s non-
parametric correlation coefficient was used. The
Kaplan–Meier procedure and log rank testing were per-
formed to estimate and correlate postoperative PCC-free
survival (metastases-free interval). For this purpose the
occurrence of metastases was defined as the end-point.
The end of follow-up or mortality due to unrelated or
unknown causes were censored. P values less than
0.05 were considered significant.
Results
Patient characteristics (Table 1)
Seventy-one unilateral and 16 bilateral resections for
103 PCCs were executed. Median duration of symptoms
was 38 (0 –420) months. Longer delays were not
associated with higher levels of plasma CATs or Chr-A.
Nor did these levels show correlation with any of the
presenting symptoms or signs. In 81 cases, 24-h
urinary assays for CAT metabolites were also per-
formed. Median follow-up on 1 September 2001 was
120 months. MEN2A was suspected and genetically
confirmed in 12 cases. As part of a previous study
(33), 36 additional patients with sporadic tumours
had RET proto-oncogene analysis, revealing no other
germline mutations. VHL tumour suppressor gene
analysis was performed in 68 patients (34), revealing
missense mutations in six.
In 14 of 87 patients at risk, metastases were diag-
nosed after a median disease-free interval of 29
months. Two of these 14 patients had only locoregional
lymph node metastases in their resection specimens. In
12 other patients, localisation studies revealed distant
metastases (multiple sites: n  7; liver: n  2; lung:
n  3). Elevation of plasma CAT and/or urinary
metabolites recurred in eight cases and persisted at
above normal values in three cases. In three cases,
metastases were non-productive. Ten patients have
Table 1 Demographic characteristics. Values are expressed as
median (range).
Demographic feature Number
Patients (M/F)/PCCs 87 (39/48)/103
Malignant: pts/tumours 14/14
Benign (FU . 5 years): pts/tumours 60/75
Disease free (FU , 5 years): pts/tumours 13/14
Resections (unilateral/bilateral) 87 (71/16)
Laparotomy 62
Thoracolaparotomy 7
Lumbotomy 2
Laparoscopy 12
Autopsy 4
Age at resection 46 years (9–78)†
Follow-up 120 months (3–192)
Syndromes
MEN2 12
VHL 6
NF 9
Symptoms at presentation*
Hypertension 57/87
Palpitations 48/87
Perspiration 46/87
Headache 36/87
Blanching 36/87
Nausea 30/87
Tremors 19/87
Vertigo 1/87
Miscellaneous 5/87
Duration of symptoms 38 months (0–420)*
Urinary CAT metabolites (fold increase)a
VMA 4.2 (0.7–25.0)‡
Normetanephrine 10.7 (1.0–59.0){
Metanephrine 9.0 (1.0–79)k
*Correlations with CAT levels and Chr-A not statistically different; †statisti-
cally significant correlation with NE r  0:245; P  0:026 and EPI r 
0:27; P  0:017; ‡statistically significant correlation with NE r  0:64;
P , 0:0005 and DA r  0:67; P , 0:0005; {statistically significant corre-
lation with NE r  0:71; P  0:01 and DA r  0:61; P  0:04; kstatisti-
cally significant correlation with EPI r  0:57; P  0:05:
a VMA, normetanephrine and metanephrine urinary levels were determined
in 66, 15 and 15 patients respectively.
FU, follow-up; pts, patients.
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died after a median postoperative interval of 68
months. Two patients are still alive despite widespread
metastatic disease. Both patients with only locoregional
metastases have been in complete remission since
operation.
Of the 73 patients with benign PCCs, 60 patients
have shown no signs of recurrence or metastases
during a minimum follow-up of 5 years. Thirteen
cases have so far been disease free, but follow-up has
been less than 5 years. Postoperatively, plasma CAT
and/or urinary CAT metabolites normalised in all but
one benign case. This case had a benign recurrence
in the contralateral adrenal gland 3 years after resec-
tion of an NE-secreting PCC.
Preoperative CAT secretion levels in benign and
malignant PCCs (Table 2)
Basal plasma CAT levels were measured in 87 patients.
Measurements of ALAAD, DOPA, DBH and Chr-A were
available in 46, 42, 44 and 39 cases respectively. One
or more basal plasma CAT levels were elevated in
81/87 instances (sensitivity: 93%).
In six cases, normal preoperative basal plasma CAT
levels were recorded, despite histopathological proof of
PCCs. None of these cases had elevated 24-h urinary
CAT metabolites. Four of these six cases with normal
CAT levels were subsequently shown to have PCC
tumours smaller than 1 cm. Three of them were
MEN2 cases, diagnosed during screening by positive
localisation studies, whereas one sporadic case had a
positive 123I-MIBG scan, while plasma CAT levels
became elevated only after glucagon stimulation. Two
others were asymptomatic sporadic cases, incidentally
discovered on CT scans.
Preoperative levels of NE, DA and ALAAD in malig-
nant PCCs were significantly higher and more fre-
quently elevated than in benign cases. In contrast,
the ratio between EPI to EPI plus NE (EPI/EPI  NE)
was significantly lower in the malignant group.
Figure 1 shows Kaplan–Meier estimates of the post-
operative metastases-free interval for patients at risk.
This interval was significantly shorter in patients with
lower than median preoperative levels of EPI/EPI  NE
(P  0:002 by the log rank test), higher levels of DA
P  0:002; NE P  0:0001 and ALAAD P 
0:022:
Basal CAT levels and clinical features (Table 3)
Patients with hereditary tumours (MEN2, VHL and NF)
had lower preoperative NE and DA levels than patients
with sporadic PCCs. Preoperative hypertension was
present in 70% of cases. NE, EPI and DA levels were sig-
nificantly higher in hypertensive than normotensive
cases, whereas Chr-A levels did not differ between the
two groups. NE and DA levels were significantly more
increased in patients with left ventricular hypertrophy
and in cases in whom cardiovascular emergencies
had occurred before operation. Furthermore, these
levels differed significantly between groups with par-
ticular modes of presentation. The highest levels were
Table 2 Preoperative plasma CAT levels in malignant, benign and disease-free tumours. Values are median (range).
Benign PCCs
PCC secretion Malignant PCCs Benign PCCs P* FU . 5 years FU , 5 years P†
NE
Elevation 14/14 51/73 0.003‡ 44/60 7/13 0.004k
Median level (pg/ml) 7629(3015–19 762) 1281 (115–155 240) ,0.0005† 1335 (236–155 240) 869 (115–17 044) ,0.0005{
EPI
Elevation 8/14 48/68 ns 40/55 8/13 ns
Median level (pg/ml) 294 (10–9100) 265 (14–11 200) ns 266 (14–11 200) 225 (28–11 073) ns
EPI/(EPI  NE) 2.12% (0.1–43.8%) 15.9% (0.3–80.5%) 0.001k 15.4% (0.3–78.0%) 23.8% (1.1–80.5%) 0.003{
DA
Elevation 11/14 21/66 0.001‡ 18/54 3/12 0.005‡
Median level (pg/ml) 232 (55–4330) 41 (1–3400) ,0.0005k 43 (1–3400) 36 (5–472) 0.001{
ALAAD
Elevation 6/11 3/35 0.001‡ 3/35 — 0.001‡
Median level (mU/I) 61 (15.6–330.8) 30 (12–236) 0.01k 30 (12.0–235.0) — 0.01k
DOPA
Elevation 6/11 15/31 ns 15/31 — ns
Median level (pg/ml) 2852 (20–83 100) 3300 (898–77 900) ns 3241 (898–77 900) — ns
DBH
Elevation 6/11 24/33 ns 24/33 — ns
Median level (U/I) 43 (13–362) 29 (7–232) ns 31 (7.0–232) — ns
Chr-A
Elevation 8/10 20/29 ns 20/29 — ns
Median level (U/I) 151 (17.9–864) 46 (13–2500) ns 46 (113.4–2500) — ns
*Malignant versus all benign cases; †malignant cases versus benign cases with postoperative follow-up (FU) periods longer and shorter than 5 years.
‡Chi-square test; {Kruskal–Wallis H test; kMann–Whitney U test; ns, not significant.
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measured in patients who were admitted for malignant
hypertension, followed by patients analysed for sus-
tained hypertension or for typical paroxysms. The
lowest NE and DA levels were encountered in asympto-
matic patients, whose tumours were more or less inci-
dentally discovered or diagnosed in an early stage
during a family screening programme.
Basal CAT levels and blood pressure
measurements (Table 4)
Significant correlations were found for all CATs and the
highest recorded preoperative diastolic and systolic
blood pressures, prior to initiating a-adrenergic block-
ade. Despite a-adrenergic blockade, significant but
slight intraoperative correlations with CAT levels were
found in case of preinduction diastolic (NE), preinduc-
tion systolic (NE, DA) blood pressure measurements
and the highest intraoperative systolic blood pressure
peak (DA) during tumour manipulation.
Basal CAT levels and parameters of tumour
size (Table 5)
Median tumour volume, largest axis and weight were
110.7 cm3, 5.4 cm and 133.2 g respectively. All par-
ameters of size were significantly correlated with CAT
plasma concentrations and except for the largest axis
also with Chr-A.
Basal CAT levels and tumour characteristics
(Table 6)
Secretion of EPI was found to be lower in ectopic PCCs
than in intra-adrenally located tumours. As opposed to
unilateral tumours, bilateral tumours secreted lower
Figure 1 Metastases-free period (Kaplan–Meier graphs). Kaplan–Meier estimates of the metastases-free interval according to the
percentage of EPI/EPI  NE and the levels of NE (normal: ,600 pg/ml), DA (normal: ,100 pg/ml) and ALAAD (normal: ,59 mU/l).
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Table 3 Clinical features: correlations with basal CAT and Chr-A levels. Values are median (range).
Clinical feature NE (pg/ml) P EPI (pg/ml) P DA (pg/ml) P Chr-A (U/I) P
MEN2 or VHL or NF*
Present n  27 1201 (115–8332) 173 (17–4438) 39 (1–285) 36 (15.4–279)
Absent n  60 3505 (236–155 240) 0.03 336 (10–11 200) ns 88 (4–4330) 0.006 65 (17.9–2500) ns
Hypertension*
Present n  61 3385 (247–155 240) 442 (12–11 200) 106 (6–4330) 61 (13.4–2500)
Absent n  26 647 (115–28300) 0.002 80 (14–1351) 0.002 23 (1–303) ,0.0005 41 (15.4–175) ns
Cardiovascular emergency*
Present n  12 7548 (575–155 240) 398 (37–11 021) 262 (25–763) 44 (15.4–864)
Absent n  75 1478 (115–27 600) 0.003 245 (10–11 200) ns 49 (1–4330) 0.01 75 (17.0–2500) ns
Left ventricular hypertrophy*
Absent n  62 1214 (247–155 240) 227 (12–11 073) 39 (1.0–1200) 40 (17.0–174)
Present n  25 6800 (583–27 600) ,0.0005 452 (10–11 200) ns 271 (33–4330) ,0.0005 134 (13.4–2500) 0.02
Presentation†
Asymptomatic n  12 614 (236–2822) 57 (16–625) 16 (4.0–58.0) 99 (22.2–175)
Hypertension analysis
n  16
3571 (746–12 469) 225 (10–9100) 105 (29.0–4330) 58 (26.6–362)
Paroxysms n  53 1920 (115–155 240) 452 (12–11 200) 60 (1.0–3400) 56 (13.4–2500)
Malignant hypertension
n  6
11472 (1155–25 600) 0.004 304 (37–1170) 0.09 278 (160–378) 0.001 40 (15.4–864) ns
Persistent hypertension*
Absent n  53 1742 (115–155 240) 172 (14–11 200) 35 (1.0–3400) 44 (20.7–277)
Present (n = 30) 3505 (280–25 600) ns 452 (10–11 200) ns 161 (27–4330) ,0.0005 103 (15.4–2500) ns
*Mann–Whitney U test; †Kruskal–Wallis H test; ns, not significant.
Table 4 Perioperative blood pressure correlations with CAT and Chr-A levels.
Highest BP
(median^S.D.) NE P EPI P DA P Chr-A P
Preoperative
Systolic BP
170^41 mmHg r  0.58 ,0.0005 r  0.29 0.02 r  0.64 ,0.0005 r  0.10 ns
Diastolic BP
103^25 mmHg r  0.61 ,0.0005 r  0.33 0.009 r  0.71 0.0005 r  20.06 ns
Preinduction
Systolic BP
150^32 mmHg r  0.30 0.01 r  0.03 0.82 r  0.33 0.01 r  0.34 ns
Diastolic BP
83^17 mmHg r  0.28 0.02 r  0.02 0.88 r  0.23 0.07 r  0.12 ns
Tumour manipulation
Systolic BP
186^40 mmHg r  0.20 ns r  0.22 0.07 r  0.28 0.02 r  0.16 ns
Diastolic BP
99^22 mmHg r  0.20 ns r  20.02 ns r  0.24 ns r  20.12 ns
Increase of systolic BP
61^38 mmHg r  0.01 ns r  0.10 ns r  0.22 ns r  0.07 ns
Increase of diastolic BP
27^17 mmHg r  0.08 ns r  0.03 ns r  0.08 ns r  0.03 ns
r, correlation coefficient; BP, blood pressure; ns, not statistically significant.
Table 5 Tumour size correlations with CAT and Chr-A levels.
Size
(median^S.D.) NE P EPI P DA P Chr-A P
Largest axis r  0.42 ,0.0005 r  0.22 0.05 r  0.44 ,0.0005 r  0.18 ns
(5.4^3.1 cm)
Volume r  0.38 0.001 r  0.35 0.002 r  0.37 0.001 r  0.34 0.04
(110.7^305.6 cm3)
Weight r  0.47 0.003 r  0.50 0.002 r  0.45 0.007 r  0.67 0.006
(133.2^265.1 g)
Tumour volume was calculated according to the formula: D1 £ D2 £ D3 £ p=6; where D1–3 represent the three dimensions of the resected tumours.
r, correlation coefficient; ns, not significant.
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amounts of DA and EPI. Intratumoural necrosis was
more frequently present in tumours producing higher
levels of all sorts of CATs. Ingrowth or full capsular per-
foration of the tumour correlated with higher levels of
NE and DA. No differences were found between
secretion patterns of tumours with or without angio-
invasion. In PCCs with haemorrhagic or cystic degener-
ation, DA, ALAAD and DBH were significantly more
elevated.
Discussion
The present study intended to correlate endocrine
activity of PCCs with clinical characteristics, tumour
morphology and tumour behaviour. Overall, basal
CAT levels were elevated in 93% of cases. In only six
cases were these levels normal, despite histopathologi-
cal diagnosis of PCCs. Notably, all of these latter cases
had normal urinary CAT metabolites as well, but
PCCs were more or less incidentally diagnosed by CT
and MIBG scans in three sporadic cases and during
family screening in three MEN2 cases. In four of these
six cases, tumours were smaller than 1 cm, this has
been arbitrarily referred to as micronodular medullary
hyperplasia, the PCC-precursing lesion in the adrenal
medulla in MEN2 (35) and sporadic (36, 37) cases.
The following correlations of plasma markers and
clinicopathological features of PCCs could be established.
Malignancy and CAT levels
Histopathological analysis of a primary tumour cannot
reliably distinguish malignant from benign PCCs.
Unambiguous proof of distant or nodal metastases is
the only reliable evidence of malignancy. For practical
purposes, massive local tumour invasion, resulting in
irresectability, can be regarded as a criterion for malig-
nancy. As effective treatment modalities are lacking,
prognosis becomes very poor as soon as metastases
have occurred (5-year survival: 23%) (20). Obviously,
persistent or recurrent high levels of CATs or their
metabolites should alert clinicians to recurrent or
metastasised disease. Therefore, predicting malignancy
before the occurrence of metastases would be of con-
siderable clinical importance. In this study, the
secretory profiles of PCCs that turned out to be malig-
nant differed significantly from benign tumours. DA
production, representing more premature CAT
secretion, was confirmed to be predictive of the pre-
sence and future occurrence of metastases (16, 19,
38, 39). Furthermore, we have found malignant PCCs
to secrete statistically higher levels of NE. Although
this has been occasionally reported by others (20), in
most studies no NE secretion differences were reported
between benign and malignant PCCs (4, 19). The ratio
EPI/EPI  NE, which serves as an index of tumour
differentiation, has been claimed to have predictive
impact for the presence of malignancy (20). In the pre-
sent study, the prognostic value of this ratio was con-
firmed. Theoretically, other constituents of the CAT
biosynthesis pathway would be better markers for an
immature pattern of CAT secretion. This has been the
first study to establish ALAAD as a preoperative
marker of malignancy in PCCs. We found DOPA
levels, which like ALAAD have been associated with
tumour recurrence in resected neuroblastomas (25),
to be similar in benign and malignant PCCs. Further-
more, neither Chr-A nor DBH proved to be associated
with malignant behaviour.
Mode of presentation, symptoms, clinical
work-up and CAT secretion pattern
Symptoms associated with PCC are often vague, and
the correct diagnosis is frequently delayed. A long
delay before PCC was properly diagnosed has been
associated with a higher chance of developing metas-
tases (19). In the present study, the CAT production
profile was not related to the duration or the particular
symptoms of PCC paroxysms. Other investigators have
reported correlations between predominant EPI
secretion and paroxysmal hypertension (40). In our
study, significantly higher basal plasma levels of NE
and DA were detected in patients presenting with
malignant hypertension, whereas values were lower
in patients presenting with only paroxysms or sus-
tained hypertension. The lowest levels were found in
PCCs which were incidentally discovered or diagnosed
in an early stage through familial screening.
Data on correlations between CAT production and
left ventricular hypertrophy are scarce. A recent
paper reports its presence in 25% of PCC cases (41).
Our data indicate left ventricular hypertrophy to be
associated with higher plasma levels of NE, DA and
Chr-A. Some authors have suggested that CATs exert
a direct effect on myocardial growth (42). Others
were, however, unable to show correlations between
NE and EPI plasma levels and the presence of left ven-
tricular hypertrophy (43).
Perioperative blood pressure measurements
and CAT levels
Not surprisingly, before the start of a-adrenergic block-
ade, positive correlations were established between
levels of CATs and the highest recorded preoperative
diastolic and systolic blood pressures. Correlation co-
efficients were the highest for NE and DA. Chr-A
levels did not show an association with measured
blood pressure values. In other studies, PCCs with pre-
dominant NE secretion have been associated with the
highest degree of haemodynamic instability during
resection (12). We did not find NE levels to correlate
with intraoperative blood pressure peaks. Only levels
of DA, of which the haemodynamic effects are less
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strongly affected by a-adrenergic blocking, showed a
slight correlation with systolic blood pressure peaks
during tumour manipulation.
Tumour size and CAT levels
A positive linear correlation was established between
preoperative plasma CAT levels and tumour size.
Although this association makes sense and has been
previously reported for urinary CAT metabolites (44),
the literature on this subject is confusing. In two
papers reporting large series of over 50 cases, no corre-
lation between the tumour size and concentrations of
CATs excreted in urine (45) and plasma (40) was estab-
lished. Others observed positive relationships between
tumour mass and plasma (nor-)metanephrines, but
not with plasma NE and EPI (8, 9, 46). Therefore,
tumour size was claimed to be a determinant for the
rate of metabolisation of CATs into free metanephrines,
but not of CAT secretion itself (8). In these investi-
gations, however, DA levels were not determined.
Morphological aspects of PCCs and CAT levels
We found no correlations between basal CAT levels and
PCCs showing angioinvasion. NE and DA levels were,
however, significantly higher in locally aggressive
PCCs showing capsular invasion and in malignant
PCCs. Others have found capsular invasion to be predic-
tive of malignancy (47). Necrosis within resected PCCs
has been established as an unfavourable prognostic
factor (5, 47). As in malignant PCCs, we found NE,
DA and ALAAD levels to be significantly higher in
PCCs with areas of necrosis. Degeneration in PCCs
with pseudocyst formation is often present (5). It has
been correlated with higher EPI levels (15) and appears
to be causative for the paroxysmal release of CATs and
sudden rise of blood pressure. In the present study,
higher levels of DA, ALAAD and DBH were detected
in tumours with cystic degeneration, but EPI levels
were not different.
Ectopic and syndrome-related PCCs and CAT
levels
Preoperative differentiation between extra-adrenal and
intra-adrenal tumours remains troublesome, particu-
larly for juxta-renal ectopic PCCs (48). Even in experi-
enced hands almost 20% of the extra-adrenal PCCs
remained undetected using contrast-enhanced CT
(49). Extra-adrenal PCCs are multicentric in up to
25% of cases and non-functional ectopic localisations
are not exceptional (48). Furthermore, extra-adrenal
PCCs are more likely to be malignant than those
found within the adrenal gland (48). Therefore,
additional parameters to differentiate extra-adrenal
from intra-adrenal PCCs preoperatively would be help-
ful, in order to focus attention on localising multifocalTa
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tumours and metastases. In the present study, median
EPI production was found to be five times lower in
extra-adrenally located PCCs than in intra-adrenal
tumours P  0:008: This finding may be at least
partly attributed to MEN2-related PCCs, which are
commonly intra-adrenally located (50) and predom-
inantly EPI secreting (44). However, even considering
only sporadic PCC cases n  60; a statistically signifi-
cant positive correlation between intra-adrenal site and
EPI production remained present (P  0:014; data not
shown). Unlike other investigators, we have been
unable to establish a positive association between NE
production and extra-adrenal site (20, 51).
We found significantly lower preoperative DA and
EPI levels in patients with involvement of both adrenal
glands than patients (so far) operated for a unilateral
tumour. Patients with already established hereditary
tumour syndromes had lower DA and NE levels than
patients operated for sporadic PCCs. This indicates
that PCCs in these patients are diagnosed at an earlier
stage of disease than their unilateral, sporadic
counterparts.
In conclusion, the present study has shown that
determination of basal plasma CAT levels has an
important place in the diagnostic work-up of PCCs.
Overall, a sensitivity of 93% is reasonable and those
tumours producing normal CAT levels n  6 were
smaller than 1 cm in four cases and all but one was
asymptomatic. In malignant PCCs, elevation of NE,
DA and ALAAD levels occurred more frequently and
values were significantly higher than in benign cases.
In contrast, the ratio EPI/EPI  NE was significantly
lower in malignant tumours. PCCs associated with
hereditary tumour syndromes secreted lower levels of
NE and DA. Furthermore, plasma CAT levels differed
significantly, according to mode of presentation, the
presence of left ventricular hypertrophy, perioperative
blood pressures and the size of the resected PCCs. Differ-
ent secretion patterns were also established for particu-
lar morphological changes in benign and malignant
PCCs.
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